Literature DB >> 7541829

Primary haemostasis in thyroid disease.

B Myrup1, C Bregengård, J Faber.   

Abstract

OBJECTIVES: There have been reports on a bleeding tendency in hypothyroidism resembling von Willebrand's disease. The aim of the present study was to investigate whether altered primary haemostasis is a general phenomenon in thyroid disease. DESIGN/
SETTING: A total of 10 patients with hyperthyroidism and nine patients with hypothyroidism were studied at diagnosis, and during treatment with carbimazole or L-thyroxine, respectively, when euthyroidism had been achieved.
RESULTS: In untreated hypothyroidism, template bleeding time was prolonged (median 9.3 min, range 3.8-20.0 min) compared to that in controls (median 4.0 min, range 3.0-6.0 min; P < 0.05), whereas maximal agglutination velocity induced by ristocetin was decreased (38% min-1, range 4-52% min-1 vs. 70% min-1, range 60-81% min-1, P < 0.05). The level of von Willebrand factor antigen in plasma from hypothyroid patients was less than half of the value in hyperthyroid patients. This difference disappeared after euthyroidism was achieved.
CONCLUSIONS: We found that changed primary haemostasis is a general feature of hypothyroidism, and that it is resolved after levothyroxine treatment.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7541829     DOI: 10.1111/j.1365-2796.1995.tb00899.x

Source DB:  PubMed          Journal:  J Intern Med        ISSN: 0954-6820            Impact factor:   8.989


  14 in total

Review 1.  Thyroid-associated autoimmune coagulation disorders.

Authors:  Massimo Franchini; Giuseppe Lippi; Franco Manzato; Pier Paolo Vescovi
Journal:  J Thromb Thrombolysis       Date:  2009-03-10       Impact factor: 2.300

2.  Endothelial dysfunction in subjects with subclinical hyperthyroidism.

Authors:  E Coban; M Aydemir; G Yazicioglu; M Ozdogan
Journal:  J Endocrinol Invest       Date:  2006-03       Impact factor: 4.256

3.  Lymphocyte-to-monocyte ratio prior to radioiodine ablation in low- and intermediate-risk, papillary thyroid cancer.

Authors:  Keunyoung Kim; Kyoungjune Pak; In-Joo Kim; Mijin Kim; Bo Hyun Kim; Byung-Joo Lee; Seong-Jang Kim
Journal:  Endocrine       Date:  2020-05-05       Impact factor: 3.633

4.  Investigation of tissue factor and other hemostatic profiles in experimental hypothyroidism.

Authors:  A Ata Alturfan; Ebru Emekli Alturfan; Nuran Dariyerli; Emel Zengin; Erman Aytac; Gunnur Yigit; Emine Kokoglu
Journal:  Endocrine       Date:  2006-08       Impact factor: 3.633

Review 5.  Hemostasis and thyroid diseases revisited.

Authors:  M Franchini
Journal:  J Endocrinol Invest       Date:  2004-10       Impact factor: 4.256

6.  Increased thrombin-activatable fibrinolysis inhibitor and decreased tissue factor pathway inhibitor in patients with hypothyroidism.

Authors:  Cihangir Erem; Ozge Ucuncu; Mustafa Yilmaz; Mustafa Kocak; Irfan Nuhoglu; Halil Onder Ersoz
Journal:  Endocrine       Date:  2008-10-29       Impact factor: 3.633

Review 7.  Thyroid, hemostasis and thrombosis.

Authors:  F Marongiu; C Cauli; S Mariotti
Journal:  J Endocrinol Invest       Date:  2004-12       Impact factor: 4.256

8.  Increased thrombin-activatable fibrinolysis inhibitor and decreased tissue factor pathway inhibitor and thrombomodulin levels in children with hypothyroidism.

Authors:  Bülent Alioğlu; Nevin Kılıç; Enver Şimşek; Yıldız Dallar
Journal:  J Clin Res Pediatr Endocrinol       Date:  2012-09

9.  A cross-sectional survey of relationship between serum TSH level and blood pressure.

Authors:  D Liu; F Jiang; Z Shan; B Wang; J Wang; Y Lai; Y Chen; M Li; H Liu; C Li; H Xue; N Li; J Yu; L Shi; X Bai; X Hou; L Zhu; L Lu; S Wang; Q Xing; W Teng
Journal:  J Hum Hypertens       Date:  2009-06-25       Impact factor: 3.012

10.  Homocysteine and fibrinogen changes with L-thyroxine in subclinical hypothyroid patients.

Authors:  Başak Cakal; Erman Cakal; Berrin Demirbaş; Mesut Ozkaya; Selma Karaahmetoğlu; Rüştü Serter; Yalçin Aral
Journal:  J Korean Med Sci       Date:  2007-06       Impact factor: 2.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.